Dajani A., Ferrieri P., Wannamaker L.Natural history of impetigo II. Etiologic agents and bacterial interactions . J Clin Invest.1972;51:2863-2871.
2.
Tunnessen W.Cutaneous infections. Pediatr Clin North Am.1983;3:515-532.
3.
Tunnessen W.Practical aspects of bacterial skin infections in children. Pediatr Dermatol.1985;2:255-265.
4.
Dillon HCImpetigo contagiosa: suppurative and nonsuppurative complications. I. Clinical, bacteriologic and epidemiologic characteristics. Am J Dis Child.1968;115:530-541.
5.
Finnerty EF, Folan DW Jr. Changing antibiotic sensitivities of bacterial skin diseases: office practice 1977-1978. Cutis. 1979;23:227-230.
6.
Schachner L. , Taplin D., Scott G., et al. A therapeutic update of superficial skin infections. Pediatr Clin North Am.1983 ;30:397-404.
7.
Barton LL, Friedman ADImpetigo: a reassessment of etiology and therapy. PediatrDermatol.1987;4:185-188.
8.
Rogers M., Dorman DC, Gapes M., et al. A three-year study of impetigo in Sydney. Med J Aust.1987;147:63-65.
9.
Grossman KL, Rasmussen JERecent advances in pediatric infectious disease and their impact on dermatology . J Am Acad Dermatol.1991 ;24:379-389.
10.
Ohana N., Keness J., Verner E., et al. Skin-isolated, community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin. J Am Acad Dermatol.1989;3:544-546.
Lacey RW, Keyworth N., Lincoln C.Staphylococcus in the U.K.: a review. J Antimicrob Chemother . 1984;14:19-25.
13.
Savath LD, Garner C., Wilcox C., et al. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. J Antimicrob Chemother. 1976;9:962-969.
14.
McBride ME, Schaefer D., Rudolph AH, et al. Evaluation of antibacterial sensitivity testing methods for methicillin-resistant Staphylococcus aureus in a dermatology outpatient population . South Med J.1989;82:165-168.
15.
Hansman D.Chemotherapy of streptococcal infections: implications of antimicrobrial drug resistance in Streptococcus pyogenes. Med J Aust.1989;150:611-612.
16.
Jarvinen H. , Nissinen A., Houvinen P.Erythromycin resistance in group A streptococci . Lancet. 1989;1:1022-1023.
17.
Barton LL, Friedman AD, Sharkey AM, et al. Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr Deramatol.1989;6:134-138.
18.
Clayton JP, Oliver RS, Rogers NH, et al. The chemistry of pseudomonic acid. Part 3. The rearrangement of pseudomonic acid A in acid and basic solution. J Chem Soc (Perkin1). 1979 ;1:838-846.
19.
Leyden JJMupirocin: a new topical antibiotic. Semin Dermatol.1987;1:48-54.
20.
Hughes J., Mellows G.On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J Antibiot. 1978 ;31:330-335.
21.
Hughes J., Mellows G.Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J.1978;176:305-318.
22.
Jackson D., Tasker Tcg, Sutherland R., et al. Clinical pharmacology of Bactroban: pharmacokinetics, tolerance and efficacy studies. In: Dobson RL, Leyden JJ, Nobel WC, Price JD, eds. Bactroban (Mupirocin). Proceedings of an International Symposium, Nassau, 1984. New York: Elsevier Science Publishing Co (Excerpta Medica); 1985:54-67. Current Clinical Practice Series, no. 16.
23.
Pappa KAThe clinical development of mupirocin. J Am Acad Dermatol.1990;22:873-879.
24.
Sutherland R., Boon RJ, Griffin KE, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use . Antimicrob Agents Chemother.1985;27:495-498.
25.
Rumsfield J. , West DP, Aronson IKTopical mupirocin in the treatment of bacterial skin infections. Drug Intell Clin Pharm.1980 ;20:943-948.
26.
Parenti MA, Hatfield SM, Leyden JJMupirocin: A topical antibiotic with a unique structure and mechanism of action . Clin Pharmacol.1987;6:761-769.
27.
Ward A., Campoli-Richards DMMupirocin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986 ;32:425-444.
28.
White AR, Beale AS, Boon RJ, et al. Antibacterial activity of mupirocin, an antibiotic produced by Pseudomonas fluorescens. In: Wilkinson T, Price JD, eds. Mupirocin — A Novel Topical Antibiotic. London: Royal Society of Medicine; 1984:43-55. International Congress and Symposium Series, no. 80.
29.
Mertz PM, Marshall DA, Eaglstein WH, et al. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol.1989;125:1069-1073.
30.
McLinn S.Topical mupirocin vs systemic erythromycin treatment for pyoderma . Pediatr Infect Dis J1988;7:785-790.
31.
Goldfarb J. , Crenshaw D., O'Horo J., et al. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother.1988;32:1780-1783.
32.
Britton JW, Fajardo JE, Krafte-Jacobs B.Comparison of mupirocin and erythromycin in the treatment of impetigo . J Pediatr.1990;117:827-829.
33.
Rice TD, Duggan KA, DeAngelis C.Cost effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Am J Dis Child.1990 ;144:443-444 (A).
34.
Kennedy Ctc, Watts JA, Speller Dce.Bactroban ointment in the treatment of impetigo: a controlled trial against neomycin. In: Dobson RL, Leyden JJ, Nobel WC, Price JD, et al. Bactroban (Mupirocin). Proceedings of an International Symposium, Nassau, 1984. New York, NY Elsevier Science Publishing Co (Excerpta Medica). 1985:125-129.
35.
Wainscott G., Huskisson SCA comparative study of Bactroban ointment and chlortetracycline cream . In: Dobson RL, Leyden JJ, Nobel WC, Price JD, eds. Bactroban (Mupirocin). Proceedings of an International Symposium, Nassau, 1984. New York: Elsevier Science Publishing Co (Excerpta Medica); 1985:137-140. Current Clinical Practice Series, no. 16.
36.
Welsh O., Saenz C.Topical mupirocin compared with ampicillin in the treatment of primary and secondary skin infections. CurrTherRes.1987 ;41:114-120.
37.
Arredondo JLEfficacy and tolerance of topical mupirocin compared with oral dicloxacillin in the treatment of primary skin infections . Curr Ther Res.1987;41:121-127.
38.
Guertin-LaRochelle S.Efficacy and tolerance of topical Bactroban (2% mupirocin) versus systemic cloxacillin in the treatment of primary and secondary skin infections. Today's Therapeutic Trends.1986;4(3):1-14.
39.
Morley Par, Munot LDA comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin. 1988;11:142-148.
40.
Gilbert M.Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol.1989;20:1083-1087.
